Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

Alec­tor re­port­ed a Phase 2 fail­ure for an Ab­b­Vie-part­nered Alzheimer’s pro­gram Mon­day af­ter­noon and said it will ...

Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.

Investing.com -- Alector Inc.宣布，其用于早期阿尔茨海默症治疗的AL002药物的二期临床试验未能达到减缓疾病进展的主要目标。受此消息影响，该公司股价在盘后交易中暴跌32%。 这家生物制药公司表示，由于试验未能达到主要终点，将终止AL002的长期延伸研究。针对这一发展，Alector还透露计划裁减约17%的员工。

南旧金山 - 专注于神经退行性疾病的生物科技公司Alector, Inc.

As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues ...